Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone301-366-4841
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$260,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable
Seneca Biopharma (NASDAQ:SNCA) Frequently Asked Questions
What is Seneca Biopharma's stock symbol?
Seneca Biopharma trades on the NASDAQ under the ticker symbol "SNCA."
When is Seneca Biopharma's next earnings date?
Has Seneca Biopharma been receiving favorable news coverage?
News stories about SNCA stock have been trending extremely negative on Wednesday, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Seneca Biopharma earned a news impact score of -4.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Seneca Biopharma.
Are investors shorting Seneca Biopharma?
Seneca Biopharma saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 90,300 shares, an increase of 259.8% from the January 15th total of 25,100 shares. Based on an average daily volume of 2,210,300 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.4% of the shares of the company are sold short. View Seneca Biopharma's Current Options Chain.
Who are some of Seneca Biopharma's key competitors?
What other stocks do shareholders of Seneca Biopharma own?
Who are Seneca Biopharma's major shareholders?
Seneca Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (6.70%).
Which major investors are buying Seneca Biopharma stock?
SNCA stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
How do I buy shares of Seneca Biopharma?
Shares of SNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Seneca Biopharma's stock price today?
One share of SNCA stock can currently be purchased for approximately $0.90.
How big of a company is Seneca Biopharma?
What is Seneca Biopharma's official website?
How can I contact Seneca Biopharma?
Seneca Biopharma's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]
MarketBeat Community Rating for Seneca Biopharma (NASDAQ SNCA)
MarketBeat's community ratings are surveys of what our community members think about Seneca Biopharma and other stocks. Vote "Outperform" if you believe SNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
